AI Tool Spots Buy Signal for Amgen at $403.04

Amgen (AMGN) has caught the attention of investors after an AI-powered stock analysis tool, MK Signal, identified a buy signal for the biopharmaceutical company. The signal was triggered at $403.04 on October 5, 2026, with MK Signal noting that Amgen previously achieved a highest return of 14.90% on October 30, 2023.

Amgen is a global leader in biopharmaceuticals, specializing in the development and sale of innovative drugs for intractable diseases such as cancer, cardiovascular disease, osteoporosis, arthritis, and rare diseases. Its flagship products include ENBREL for arthritis, Prolia for osteoporosis, Repatha for cholesterol reduction, and Otezla for psoriasis. Prolia and Repatha have recently seen double-digit growth, contributing significantly to the company's sales.

The company's core competitiveness lies in its "biology first" approach, which leverages over 40 years of R&D experience and biological mechanisms. Amgen also benefits from excellent biopharmaceutical production facilities and a strong distribution network across more than 100 markets worldwide, including the United States and Canada.

Looking ahead, Amgen's revenue for 2027 is projected to increase 4% year-over-year to $40.3 billion, with earnings per share (EPS) expected to rise 12% to $17.67. For 2028, the stock market anticipates a 3% revenue increase to $41.6 billion and a 4% rise in EPS to $18.41.

Investors interested in future trading signals for Amgen can monitor the stock in real-time by installing the MK Signal app and registering it as an item of interest. MK Signal is a comprehensive securities information service that provides investment information and trading signals for 8,000 domestic and U.S. stocks.